When compared to untreated melanoma-conditioned MAFs, the small molecule inhibitors, vemurafenib, dabrafenib, and trametinib with dabrafenib, enhanced the ability of both melanoma cell lines and primary melanoma cells to stimulate MAFs, which ultimately led to an additional increase in THP-1-derived IL-10 secretion. The gene discussed is IL10; the disease is melanoma.